A human CD137×PD-L1 bispecific antibody promotes anti-tumor immunity via context-dependent T cell costimulation and checkpoint blockade
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A human CD137×PD-L1 bispecific antibody promotes anti-tumor immunity via context-dependent T cell costimulation and checkpoint blockade
Authors
Keywords
-
Journal
Nature Communications
Volume 12, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2021-07-21
DOI
10.1038/s41467-021-24767-5
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A conserved intratumoral regulatory T cell signature identifies 4-1BB as a pan-cancer target
- (2020) Zachary T. Freeman et al. JOURNAL OF CLINICAL INVESTIGATION
- FS222, a CD137/PD-L1 tetravalent bispecific antibody exhibits low toxicity and anti-tumor activity in colorectal cancer models
- (2020) Matthew A Lakins et al. CLINICAL CANCER RESEARCH
- Progress and Challenges in Precise Treatment of Tumors With PD-1/PD-L1 Blockade
- (2020) Youhai Jiang et al. Frontiers in Immunology
- The PD-1/PD-L1-Checkpoint Restrains T cell Immunity in Tumor-Draining Lymph Nodes
- (2020) Floris Dammeijer et al. CANCER CELL
- T-cell agonists in cancer immunotherapy
- (2020) Yeonjoo Choi et al. Journal for ImmunoTherapy of Cancer
- CD8 T Cell Exhaustion During Chronic Viral Infection and Cancer
- (2019) Laura M. McLane et al. Annual Review of Immunology
- Tumor-localized costimulatory T cell engagement by the 4-1BB/HER2 bispecific antibody-Anticalin fusion PRS-343
- (2019) Marlon J Hinner et al. CLINICAL CANCER RESEARCH
- Intratumoral regulatory T cells: markers, subsets and their impact on anti‐tumor immunity
- (2019) Hiroshi Yano et al. IMMUNOLOGY
- MCLA-117, a CLEC12AxCD3 bispecific antibody targeting a leukaemic stem cell antigen, induces T cell-mediated AML blast lysis
- (2019) Pieter Fokko van Loo et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Tumor-targeted 4-1BB agonists for combination with T cell bispecific antibodies as off-the-shelf therapy
- (2019) Christina Claus et al. Science Translational Medicine
- Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
- (2019) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- 4-1BB Agonism Averts TIL Exhaustion and Licenses PD-1 Blockade in Glioblastoma and other Intracranial Cancers
- (2019) Karolina I. Woroniecka et al. CLINICAL CANCER RESEARCH
- Unbiased Combinatorial Screening Identifies a Bispecific IgG1 that Potently Inhibits HER3 Signaling via HER2-Guided Ligand Blockade
- (2018) Cecile A.W. Geuijen et al. CANCER CELL
- Crystal structure of the human 4-1BB/4-1BBL complex
- (2018) Ryan N. Gilbreth et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- The promise and challenges of immune agonist antibody development in cancer
- (2018) Patrick A. Mayes et al. NATURE REVIEWS DRUG DISCOVERY
- Chimeric Antigen Receptor Therapy
- (2018) Carl H. June et al. NEW ENGLAND JOURNAL OF MEDICINE
- Structure of the 4-1BB/4-1BBL complex and distinct binding and functional properties of utomilumab and urelumab
- (2018) S. Michael Chin et al. Nature Communications
- Limited Cross-Linking of 4-1BB by 4-1BB Ligand and the Agonist Monoclonal Antibody Utomilumab
- (2018) Yan Li et al. Cell Reports
- A new approach for generating bispecific antibodies based on a common light chain format and the stable architecture of human immunoglobulin G 1
- (2017) Camilla De Nardis et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Origin and differentiation of human memory CD8 T cells after vaccination
- (2017) Rama S. Akondy et al. NATURE
- T-cell invigoration to tumour burden ratio associated with anti-PD-1 response
- (2017) Alexander C. Huang et al. NATURE
- Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody
- (2016) Neil H. Segal et al. CLINICAL CANCER RESEARCH
- Blockade of Programmed Death 1 Augments the Ability of Human T Cells Engineered to Target NY-ESO-1 to Control Tumor Growth after Adoptive Transfer
- (2015) E. K. Moon et al. CLINICAL CANCER RESEARCH
- CD137 Agonist Therapy Can Reprogram Regulatory T Cells into Cytotoxic CD4+T Cells with Antitumor Activity
- (2015) Ilseyar Akhmetzyanova et al. JOURNAL OF IMMUNOLOGY
- The future of immune checkpoint therapy
- (2015) P. Sharma et al. SCIENCE
- The ultimate radiochemical nightmare: upon radio-iodination of Botulinum neurotoxin A, the introduced iodine atom itself seems to be fatal for the bioactivity of this macromolecule
- (2015) Janneke IM van Uhm et al. EJNMMI Research
- 4-1BB Agonists: Multi-Potent Potentiators of Tumor Immunity
- (2015) Todd Bartkowiak et al. Frontiers in Oncology
- A high-throughput shotgun mutagenesis approach to mapping B-cell antibody epitopes
- (2014) Edgar Davidson et al. IMMUNOLOGY
- PD-1 identifies the patient-specific CD8+ tumor-reactive repertoire infiltrating human tumors
- (2014) Alena Gros et al. JOURNAL OF CLINICAL INVESTIGATION
- Single and Dual Amino Acid Substitutions in TCR CDRs Can Enhance Antigen-Specific T Cell Functions
- (2014) Paul F. Robbins et al. JOURNAL OF IMMUNOLOGY
- Differential Impact of CD27 and 4-1BB Costimulation on Effector and Memory CD8 T Cell Generation following Peptide Immunization
- (2014) J. E. Willoughby et al. JOURNAL OF IMMUNOLOGY
- PD-1 blockade induces responses by inhibiting adaptive immune resistance
- (2014) Paul C. Tumeh et al. NATURE
- Antigen-specific activation and cytokine-facilitated expansion of naive, human CD8+ T cells
- (2014) Matthias Wölfl et al. Nature Protocols
- Host programmed death ligand 1 is dominant over programmed death ligand 2 expression in regulating graft-versus-host disease lethality
- (2013) A. Saha et al. BLOOD
- Clinical Development of Immunostimulatory Monoclonal Antibodies and Opportunities for Combination
- (2013) I. Melero et al. CLINICAL CANCER RESEARCH
- Antagonist Antibodies to PD-1 and B7-H1 (PD-L1) in the Treatment of Advanced Human Cancer--Response
- (2013) M. Sznol et al. CLINICAL CANCER RESEARCH
- CD137 Accurately Identifies and Enriches for Naturally Occurring Tumor-Reactive T Cells in Tumor
- (2013) Q. Ye et al. CLINICAL CANCER RESEARCH
- T Cell Costimulation with Anti-CD137 Monoclonal Antibodies Is Mediated by K63-Polyubiquitin-Dependent Signals from Endosomes
- (2013) I. Martinez-Forero et al. JOURNAL OF IMMUNOLOGY
- Innate and adaptive immune cells in the tumor microenvironment
- (2013) Thomas F Gajewski et al. NATURE IMMUNOLOGY
- Co-Stimulation through 4-1BB/CD137 Improves the Expansion and Function of CD8+ Melanoma Tumor-Infiltrating Lymphocytes for Adoptive T-Cell Therapy
- (2013) Jessica Ann Chacon et al. PLoS One
- Combinatorial PD-1 Blockade and CD137 Activation Has Therapeutic Efficacy in Murine Cancer Models and Synergizes with Cisplatin
- (2013) Huafeng Wei et al. PLoS One
- Cancer Immunotherapy
- (2013) J. Couzin-Frankel SCIENCE
- 4-1BB Signaling Synergizes with Programmed Death Ligand 1 Blockade To Augment CD8 T Cell Responses during Chronic Viral Infection
- (2011) V. Vezys et al. JOURNAL OF IMMUNOLOGY
- Treatment with anti-CD137 mAbs causes intense accumulations of liver T cells without selective antitumor immunotherapeutic effects in this organ
- (2010) Juan Dubrot et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Chimeric Receptors Containing CD137 Signal Transduction Domains Mediate Enhanced Survival of T Cells and Increased Antileukemic Efficacy In Vivo
- (2009) Michael C. Milone et al. MOLECULAR THERAPY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More